iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022
PR94232
SEOUL, South Korea, Jan. 27, 2022 /PRNewswire=KYODO JBN/ --
-An innovative Wireless Brainwave Scanning & Mapping device Attracts the Media
and Public Attention from Visitors Around the World
iMediSync, A biotech startup company from Seoul, South Korea, successfully
debuted at CES 2022 to introduce the new trend of digital healthcare under
their motto – Overcome Mental Pandemic in just 10 Min.
At the event, the company presented iSyncWave, a dry EEG helmet that provides
EEG, HRV measurement equipped with the world first age/gender matching Norm DB
built with over 1,800 healthy brainwaves to provide a comparative analysis
report to the subject.
iSyncWave's main features follow below:
-Nineteen channel electrodes with gear that automatically adjust to the 10/20
system
-Age/gender matching EEG and HRV analysis & assessment report in 10 minutes
-PBM - Near InfraRed LED Therapy
During CES 2022, the company caught the attention of the media and visitors
from all over the globe. Each day, more than three hundred visitors came to the
booth including audiences such as doctors, clinicians, entrepreneurs,
YouTubers, influencers, and interested parties.
On the first day of CES, nearly one hundred visitors were able to participate
in their real-time brainwave measurement and to learn more about the brain and
QEEG.
A promising start for the iMediSync continued its momentum with interest from
all kinds of audiences including the CTA VIP tours.
The CEO Dr. Seung Wan Kang comments, "The purpose of this showcase is to
introduce our technology and our goal that we will provide life-changing mental
healthcare experience in the field of neuro-mental illness biomarker with our
patent EEG/HRV technology, we strive to provide an optimized individual mental
healthcare service in the post-Covid-19 era."
Aside from iMediSync's innovation and technology, the booth received numerous
visits from key personnel to discuss collaboration in digital healthcare fields
and to expand to the global market of brain science and neurology.
iMediSync, expecting the IPO this year has established close cooperation with
various research facilities and medical organization around the world is
continuing discussion with major pharmaceutical companies for cooperation.
With the Korean FDA approval for their product and the software, iMediSync
expects the FDA and CE approval in the first half of 2022 to expand further on
their biomarkers along with developing a next-level product to declare
themselves as a trend leader in the field.
Source: iMediSync
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=413778
Caption: Attendees waiting in the line to experience the iSyncWave at CES 2022
Link: http://asianetnews.net/view-attachment?attach-id=413780
Caption: Attendee experiencing the new iSyncWave at the iMediSync booth
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。